# Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction.

Study · id `cardio:ct-nct02768298` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02768298](<https://clinicaltrials.gov/study/NCT02768298>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02768298

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 201 participants.

## Technical summary

Registry record NCT02768298. Randomized; double masking; primary purpose treatment. Start 2016-07-12 (actual); primary completion 2019-11-25 (actual). Results posted on 2020-10-09.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 201 participants (enrolled count; ClinicalTrials.gov record NCT02768298, source copy `cardio:ctgov-nct02768298-2021-10-08`, retrieved 2026-10-26)
- Started: 2016-07-12 (actual) (ClinicalTrials.gov record NCT02768298, source copy `cardio:ctgov-nct02768298-2021-10-08`, retrieved 2026-10-26)
- Primary completion: 2019-11-25 (actual) (ClinicalTrials.gov record NCT02768298, source copy `cardio:ctgov-nct02768298-2021-10-08`, retrieved 2026-10-26)
- Completion: 2019-11-25 (actual) (ClinicalTrials.gov record NCT02768298, source copy `cardio:ctgov-nct02768298-2021-10-08`, retrieved 2026-10-26)
- Results first posted: 2020-10-09 (ClinicalTrials.gov record NCT02768298, source copy `cardio:ctgov-nct02768298-2021-10-08`, retrieved 2026-10-26)
- Countries: Germany (ClinicalTrials.gov record NCT02768298, source copy `cardio:ctgov-nct02768298-2021-10-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02768298-2021-10-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction.
- Condition: Chronic Heart Failure With Reduced Ejection Fraction
- Intervention (Drug): LCZ696
- Intervention (Drug): Enalapril
- Intervention (Drug): Placebo matching enalapril
- Intervention (Drug): Placebo matching LCZ696
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart failure with reduced ejection fraction (HFrEF) (`cardio:hfref`)
- Registry intervention name matches this record: Sacubitril/valsartan (combination) (`cardio:sacubitril-valsartan`)
- Registry intervention name matches this record: Enalapril (`cardio:enalapril`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: 024f8e2b0a8750f656a7499b2f7f65ca43e375c93b1889d510c171de8bd23b24
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
